Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agilent Technologies (NY:A)

138.51 -1.79 (-1.27%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agilent Technologies

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Completes Acquisition of Biocare Medical
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Announces Cash Dividend of 25.5 Cents per Share
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent to Supply Next Generation Alarm Resolution Technology to U.S. Airport Security Screening Checkpoints ahead of FIFA World Cup 2026
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent to Participate in Jefferies Global Healthcare Conference
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Names Michael Buckner as Chief Legal Officer
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Showcases Cancer Research Solutions at AACR 2026
From Agilent Technologies Inc.
Via Business Wire
ADM Endeavors (OTCQB: ADMQ) Reports $5.62M Revenue, Profitability Surges as Facility Expansion Drives Growth
FORT WORTH, TX - April 1, 2026 (NEWMEDIAWIRE) - ADM Endeavors (OTCQB: ADMQ), a vertically integrated provider of custom apparel, promotional products, uniforms, screen printing, embroidery, and digital... 
Via TheNewswire.com
News headline image
ADM Endeavors (OTCQB: ADMQ) Reports $5.62M Revenue, Profitability Surges as Facility Expansion Drives Growth
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
From Agilent Technologies Inc.
Via Business Wire
News headline image
Maha to Exercise the Call Option for PetroUrdaneta in Venezuela Following OFAC's Publication of General License 52
From Maha Capital AB
Via Business Wire
News headline image
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
From Agilent Technologies Inc.
Via Business Wire
News headline image
Agilent Reports First-Quarter Fiscal Year 2026 Financial Results
From Agilent Technologies Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS